| 0.351 0.015 (4.46%) | 11-28 13:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.56 | 1-year : | 0.71 |
| Resists | First : | 0.48 | Second : | 0.61 |
| Pivot price | 0.35  |
|||
| Supports | First : | 0.28 | Second : | 0.23 |
| MAs | MA(5) : | 0.32 |
MA(20) : | 0.37 |
| MA(100) : | 0.61 |
MA(250) : | 1.07 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 18.1 |
D(3) : | 15.1 |
| RSI | RSI(14): 37.5 |
|||
| 52-week | High : | 2.34 | Low : | 0.28 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CANF ] has closed above bottom band by 44.9%. Bollinger Bands are 10% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.36 - 0.36 | 0.36 - 0.36 |
| Low: | 0.33 - 0.33 | 0.33 - 0.33 |
| Close: | 0.33 - 0.34 | 0.34 - 0.34 |
Wed, 26 Nov 2025
Can-Fite’s Latest Developments of its Advanced Stage Drug - GlobeNewswire
Mon, 24 Nov 2025
Can-Fite BioPharma (CANF) to Engage in Strategic Collaborations at BioFIT 2025 - GuruFocus
Thu, 20 Nov 2025
CF602 Targets ED Non-Responders as Can-Fite (NYSE American: CANF) Wins Brazil Patent - Stock Titan
Tue, 18 Nov 2025
Why Is Can-Fite BioPharma Stock (CANF) Up Today? - TipRanks
Tue, 18 Nov 2025
Can-Fite BioPharma (NYSE American: CANF) reports 9-year Namodenoson response in HCC - Stock Titan
Tue, 11 Nov 2025
Can-Fite BioPharma Shareholders Approve Key Proposals - The Globe and Mail
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 2.94e+009 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 132 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -8.12e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 127.3 % |
| Return on Equity (ttm) | -53.2 % |
| Qtrly Rev. Growth | 674000 % |
| Gross Profit (p.s.) | 193.75 |
| Sales Per Share | -1686.75 |
| EBITDA (p.s.) | 8.425e+006 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 358510 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|